Caladrius CEO Predicts Tenfold Market Cap Rise As Pipeline ‘Validates’ Itself

The CEO of US-based Caladrius Biosciences believes its share price will rise at least tenfold over the next three years as the cell therapy specialist’s pipeline advances to commercialization.

Blood
Caladrius Biosciences develops treatments for ischemic cardiovascular disease • Source: Shutterstock

With its first product on track for approval soon in Japan, Caladrius Biosciences Inc. is planning its transition over the next three years from a late-stage developer of cell therapies to one commercializing treatments for ischemic diseases. The evolution should see the US group’s share price rise steadily as its pipeline "validates itself", CEO David Mazzo told Scrip.

Caladrius Biosciences has product candidates in development based on two technology platforms, one targeting autoimmune and one targeting cardiology indications.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Regeneron Wins PCSK9 Court Battle Against Amgen

 

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By 

As CEO Anderson backs high prices for innovative drugs in Europe

More from Therapy Areas

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By 

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.